Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02695381 · ClinicalTrials.gov registry record · Phase 3

Etodolac-lidocaine Patch in Subjects Experiencing Acute Delayed Onset Muscle Soreness

A Phase 3 study, sponsored by MEDRx USA.

Completed
Registry status
Phase 3
Development phase
100
Enrollment target

NCT02695381 is a Phase 3 study that has completed, run by MEDRx USA. The registered enrollment target is 100 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02695381, a Phase 3 study, has completed, sponsored by MEDRx USA.

COMPLETED
Registry status
Phase 3
Development phase
100 participants
Enrollment target

Study Summary

This study evaluate the efficacy and safety of Etodolac-lidocaine topical patch applied one time daily when compared with placebo in the treatment of acute Delayed Onset Muscle Soreness (DOMS) of the upper limbs.

Interventions

  • DRUG Placebo
  • DRUG Etodolac-lidocaine topical patch

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2016-03
Est. Completion 2016-09
Phase Phase 3

Sponsor

MEDRx USA

5 total trials

What the Registry Record Tells You About NCT02695381

The ClinicalTrials.gov registry entry for NCT02695381 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MEDRx USA, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02695381 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02695381 about?

NCT02695381 is a clinical study titled "Etodolac-lidocaine Patch in Subjects Experiencing Acute Delayed Onset Muscle Soreness". This study evaluate the efficacy and safety of Etodolac-lidocaine topical patch applied one time daily when compared with placebo in the treatment of acute Delayed Onset Muscle Soreness (DOMS) of the upper limbs.

What is the current status of trial NCT02695381?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2016-03. Estimated completion is 2016-09.

What interventions are being tested in trial NCT02695381?

The interventions under investigation include: Placebo (DRUG), Etodolac-lidocaine topical patch (DRUG).

Who is sponsoring clinical trial NCT02695381?

This trial is sponsored by MEDRx USA, which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.